Swiss company launches rapid test to determine Covid-19 severity
Septic shock is one of the major complications of Covid-19.
Keystone / Pablo Gianinazzi
Lausanne-based medical technology firm Abionic has created the first rapid blood test to help doctors decide whether Covid-19 patients require treatment in intensive care units.
This content was published on
2 minutes
Keystone-SDA/jdp
Español
es
COVID-19: Prueba rápida suiza detecta gravedad de pacientes
According to a presentationExternal link by Abionic, the Covid-19 Severity Score test uses a small blood sample from the fingertip to determine how serious the disease is and how likely it is to worsen. Physicians receive the test results within five minutes and could then decide whether a patient should be admitted to intensive care, transferred to a general hospital ward or discharged from the hospital.
The test is intended to ease the burden on healthcare workers and intensive care units that are reaching capacity in some countries with high numbers of Covid-19 patients.
Abionic adapted the diagnostics process it developed for the detection of sepsis, a life-threatening complication of bacterial and viral infections, for use in Covid-19 in order to provide faster results. The Covid-19 severity test is based on the “sequential organ failure assessment score” (SOFA score), which is tracked by hospitals to determine a patient’s status in intensive care units based on organ functioning.
“Already in March of this year, we noticed in many different publications that one of the most frequent causes of death in Covid-19 patients was indeed bacterial sepsis,” Abionic CEO Nicolas Durand told Reuters news agency.
The test has been validated in clinical studies involving several hundred patients in various countries and hospitals and has received approval for use in Europe.
Founded in 2010 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPFL), Abionic distributes its tests and devices mainly in Europe. The company has received almost CHF37 million ($40.7 million) from investors in three rounds of financing.
Popular Stories
More
Foreign affairs
Why Swiss trams have become sought-after vehicles in Ukraine
Switzerland participates in ASEAN foreign ministers’ meeting
This content was published on
This engagement was part of a four-day tour of Southeast Asia, aimed at advancing the Swiss Federal Council's Southeast Asia Strategy.
Majority of shareholders approve sustainability reports of major Swiss companies
This content was published on
Shareholders have approved the sustainability reports of the largest Swiss companies by a large majority at their annual general meetings.
EU releases €1.5B frozen assets to Ukraine: Switzerland opts out
This content was published on
The EU announced the release of €1.5 billion (CHF1.44 billion) in aid to Ukraine. Switzerland will not follow the EU's approach.
Five people charged in connection with deadly Swiss rockslide
This content was published on
Five people have been charged with multiple negligent homicide in connection with the deadly Bondo rockslide that occurred seven years ago.
Mountaineer dies after 100-metre fall from Matterhorn
This content was published on
A women fell down the east face of the iconic mountain on Thursday, from an altitude of some 3,460 meters above sea level.
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
The Swiss biotech shaking up the antibiotics model
This content was published on
Family-owned Debiopharm says it’s time to treat the life-saving medicine like insurance if we want to avoid another pandemic.
Intensive care staff exhausted as Covid numbers rise
This content was published on
Intensive care workers are going into the second wave of the coronavirus pandemic exhausted, the Swiss Society of Intensive Care Medicine has warned.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.